Company intelligence / Profile preview
Nanoscope Therapeutics
Dallas, Texas, United Statesnanostherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Nanoscope Therapeutics has reported positive top-line results from its RESTORE Phase 2b trial of MCO‑010 in retinitis pigmentosa, achieving primary and key secondary endpoints with statistical significance and no serious adverse events. The therapy demonstrated clinically meaningful vision improvement in legally blind individuals. A BLA submission to the FDA is planned for the second half of 2024. The company’s STARLIGHT trial of MCO‑010 in Stargardt disease has also been completed. Both indications have received FDA fast-track and orphan drug designations.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapy (optogenetic)Ambient light-sensitive molecules (Multi-characteristic opsins)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Nanoscope Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanoscope Therapeutics.